Introduction
This year alone, an estimated 29 900 men will die of prostate cancer (CaP) in the United States, and the vast majority of them will have extensive bone metastasis (Alcover et al., 1994; Abate-Shen and Shen, 2000; American Cancer Society, 2005) . Metastatic bone lesions are associated with intractable pain, bone fracture and spinal compression that can lead to paralysis (Cancer Management: A Multidisciplinary Approach, 1999; Thalmann et al., 2000) . Currently, the mechanisms that underlie CaP metastasis are poorly understood. Therefore, molecules involved in CaP cell motility and invasion must be identified to design novel therapeutic strategies for metastatic CaP. Recent studies have focused on Ras homology (Rho) kinase (a.k.a. ROCK), the downstream effector protein of the monomeric G-proteins RhoA and RhoC (Somlyo et al., 2000 (Somlyo et al., , 2003 . The ROCK inhibitor Wf-536, used in conjunction with the matrix metalloproteinase inhibitor Marimastat, significantly inhibits experimental tumor growth, tumor angiogenesis and increased survival of mice bearing PC-3 xenotransplants (Somlyo et al., 2003) . Other investigators have demonstrated that treatment of PC-3 cells with the ROCK inhibitor Y27632 retards in vitro PC-3 cell migration (Somlyo et al., 2000) . These results underscore the importance of the molecules that lie upstream of ROCK, specifically, the Rho GTPases.
The Rho GTPases belong to the Ras superfamily of small GTP binding proteins and act as molecular switches involved in all aspects of cellular motility and invasion, including polarity, cytoskeletal organization and signal transduction from the extracellular environment (Kjoller and Hall, 1999; Price and Collard, 2001; Ridley, 2001; Takai et al., 2001) . Like Ras, Rho cycles between an inactive GDP-bound and active GTP-bound state that can activate downstream effector proteins (Olson, 1996; Geyer and Wittinghofer, 1997) . To be fully effective in producing an invasive phenotype, Rho proteins need to complete a full GTPase cycle and continue to cycle, transitioning between inactive and active states (Hall, 1990; Moorman et al., 1999; Sander et al., 1999; Danen et al., 2000) . John Collard and his group elegantly demonstrated a reciprocal relationship of activation between RhoA GTPase and Rac1 (Sander et al., 1999; Zondag et al., 2000) . Therefore, although one isoform of Rho may predominate in a cancer cell, activation of other GTPases must occur during motility, migration and invasion, to effectively reorganize the cytoskeleton forming stress fibers, lamellipodia and filopodia (Nobes and Hall, 1995; Hall, 1998; Price and Collard, 2001 ).
RhoC GTPase is a Rho protein implicated in the progression and metastasis of several cancers, including breast, ovarian, pancreas, gastric cancer, hepatocellular carcinoma, bladder, colorectal and cutaneous melanoma (Moscow et al., 1994; del Peso et al., 1997; Suwa et al., 1998; Fritz et al., 1999; van Golen et al., 1999 van Golen et al., , 2000 Imamura et al., 1999; Clark et al., 2000; Sahai and Marshall 2002; Carr et al., 2003; Horiuchi et al., 2003; Kamai et al., 2003; Marionnet et al., 2003; Shinto et al., 2003; Wang et al., 2003; Kondo et al., 2004) . Our laboratory has demonstrated that ectopic expression of wild-type RhoC in immortalized human mammary epithelial cells leads to a metastatic phenotype (van Golen et al., 2000a, b) . We have also demonstrated that RhoC can be used as a prognostic marker to identify small breast tumors (o1 cm) with a high likelihood to metastasize (Kleer et al., 2002) . Recently our attention has turned to the potential role of RhoC in CaP metastasis, particularly metastasis to bone.
In several aggressive cancers, including CaP, activation of the Rho GTPases, including RhoC, occurs through protein tyrosine kinase growth factor receptor stimulation (van Golen, 2003) . Motility of many cancer cell types is stimulated by growth factors such as insulinlike growth factor I (IGF-I) (Sahai and Marshall, 2002) . Increased levels of the type I IGF receptor (IGF-IR) are found in the majority of primary and metastatic CaP patient tumors (Hellawell et al., 2002) . Functional IGF-IR is expressed on PC-3 cells (Iwamura et al., 1993; Kimura et al., 1996) , and bone is a rich source of IGF-I, which is thought to act as a chemoattractant in CaP bone metastasis (Cooper and Pienta, 2000) . CaP cells further upregulate IGF-IR expression upon localization to bone (Rubin et al., 2004) . Although the link between the IGF system and CaP progression is well established, recent new drug developments have led to renewed pharmaceutical interest in IGF signaling pathways as therapeutic targets (Zhang and Yee, 2004; Garber, 2005; Mitsiades and Mitsiades, 2005) .
In the present study, we demonstrate that RhoC is highly expressed and active in the human PC-3 cell line, which is derived from a bone metastasis. Furthermore, RhoC is responsible for IGF-I-mediated invasion of PC-3 cells but not for IGF-I-stimulated motility. Inhibition of RhoC activity leads to increased Rac1 and Cdc42 expression and activation. This in turn leads to an increase in linear motility, but decreased directed migration and invasion. Finally, inhibition of RhoC activity results in a change in the expression and cellular distribution of focal adhesion-associated proteins. These data provide insight into the potential mechanisms of CaP cell invasion, a key component in the metastatic cascade.
Results

Rho GTPase expression in CaP cells
We previously demonstrated that RhoC GTPase is a putative mammary oncogene responsible for the motile and invasive capabilities of aggressive breast cancer cells (van Golen et al., 1999 (van Golen et al., , 2000a (van Golen et al., , b, 2002 . Increasing evidence from several laboratories suggests that RhoC expression is associated with particularly aggressive, metastatic cancers; however, this has never been reported for CaP (Moscow et al., 1994; del Peso et al., 1997; Fritz et al., 1999; Imamura et al., 1999; Clark et al., 2000; Sahai and Marshall, 2002; Carr et al., 2003; Horiuchi et al., 2003; Kamai et al., 2003; Marionnet et al., 2003; Shinto et al., 2003; Wang et al., 2003; Kondo et al., 2004) . We hypothesized that RhoC may be involved in CaP metastasis. To answer this question, we screened the LNCaP, DU145 and PC-3 cell lines for RhoC expression. RhoA GTPase, a close relative of RhoC, has been implicated in PC-3 cell invasion; therefore, we also examined RhoA expression. RhoA GTPase is highly expressed at the mRNA ( Figure 1a , left panel) and protein ( Figure 1b , left panel) level in all three CaP cell lines tested. However, RhoC message was detected only in the LNCaP and PC-3 cell lines ( Figure 1a , right panel). Active, GTP-bound RhoA was detected in all three prostate cancer cell lines. In contrast, only the PC-3 cell line, which was originally derived from a skeletal metastasis, expressed active RhoC protein (Figure 1b, right panel) . Although the LNCaP cell line has detectable levels of RhoC message, it does not express appreciable levels protein, suggesting that RhoC expression and activation may be associated with the PC-3 metastatic phenotype.
RhoC GTPase activity affects PC-3 cell motility and invasion To determine whether expression of RhoC facilitates cellular motility stimulated by elements found in the 
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H Yao et al bone environment, we compared cell motility using a colloidal blue-fluorescent bead random motility assay and measured the area of phagokinetic tracks produced by the cells (Figure 2a ). The conditions of this assay were adjusted to test motility in response to insulin-like growth factor-I (IGF-I) stimulation on a collagen type I (col I)-coated surface. Both IGF-I and collagen I are present in the bone microenvironment and are implicated in facilitating CaP dissemination, adherence and survival (Kiefer and Farach-Carson, 2001; Rubin et al., 2004; Chung et al., 2005; Yin et al., 2005) . Each of the three CaP cell lines tested have functional IGF-IR (Kimura et al., 1996) . At 16 h after stimulation with 5 nM IGF-I, the PC-3 cells produced unique circular phagokinetic tracks many times the diameter of their cell bodies (Figure 2a) . Interestingly, when PC-3 cells were pretreated with C3 exotransferase, a potent inhibitor of Rho GTPases, and then stimulated with IGF-I, PC-3 cells no longer displayed a circular motility but became extremely linearly mobile ( Figure 2a) . Quantitation of the phagokinetic tracks produced by PC-3 cells demonstrated a significant increase in area in cells treated with C3 exotransferase prior to IGF-I stimulation ( Figure 2a ). This observation is contrary to what we have observed in other cell systems such as breast (van Golen et al., 2000a, b) . LNCaP cells are nonmotile, and DU145 cells demonstrate moderate linear motility that is inhibited by C3 exotransferase treatment. Since C3 exotransferase has specific affinity for the Rho proteins (RhoC>RhoA>>RhoB) and very little affinity for Rac1 or Cdc42, these data suggest that RhoC activity may negatively modulate PC-3 cell random linear motility Aktories, 1997) . In contrast, since RhoC is not expressed in the DU145 cells, inhibition of RhoA by C3 exotransferase treatment retards DU145 random linear motility. Next, we determined whether C3 treatment also affected migration in response to a chemoattractant (also termed directed motility). In this assay a Transwell chamber was used to determine the migratory capabilities of PC-3 cells through a filter with 8 mm pores using 5 nM IGF-I as a chemoattractant (Figure 2b ). We found that the PC-3 cells were highly migratory towards IGF-I. However, in contrast to the random motility assay described above, the ability of cells to migrate in response to IGF-I is significantly inhibited by C3 exotransferase treatment.
Similar results were observed when the cells were tested for haptotactic migration through an 8 mm filter with a gradient of 1 nM IGF-I in the upper chamber to 5 nM IGF-I in the lower chamber (Figure 2b ). Untreated PC-3 cells move readily toward the higher IGF-I concentration; however, C3 treatment abrogates this affect.
Finally, the cells were tested for their ability to invade through a Matrigel-or collagen I-coated filter in response to 5 nM IGF-I as a chemoattractant. In these systems, the PC-3 cells are highly invasive (Figure 2b ). C3 exotransferase treatment significantly inhibits CaP cell invasion. Taken together, these data suggest that motility and invasion in PC-3 cells are particularly regulated by different GTPases. Specifically, RhoC activity is required for directional motility toward a Figure 2 Effect of Rho GTPase activation on PC-3 cell motility, migration and invasion. Panel a shows a comparison of the motile capabilities of the CaP cells using a blue-fluorescent bead random motility assay after stimulation with IGF-I on a collagen I-coated surface. In this assay, a colloid of blue-fluorescent polymer beads are overlaid onto 96-well plates coated with collagen I. The cells are allowed to attach for 1 h in serum-free medium and then stimulated with 5 nM IGF-I. After growth factor stimulation, motile cells phagocytize the colloid and the area of the resulting phagokinetic tracks are measured 24 h later. To determine the role of Rho proteins in conferring a motile phenotype, cells were treated overnight with 10 mg C3 exotransferase, a potent inhibitor of Rho proteins. Rho inhibition significantly increased the PC-3 cells linear random motility (*P ¼ 0.001). Panel b demonstrates the results of directed migration, haptotaxis (with a gradient of 1 nM in the top chamber to 5 nM IGF-I in the lower chamber) or invasion assay through a Matrigel or collagen I-coated filter. In each assay the cells were placed in the top of a Transwell filter and migrated towards a chemoattractant. In contrast to the random motility assay, C3 treatment (gray bars) significantly decreased PC-3 movement as compared with the untreated cells (black bars, *Po0.05).
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Since C3 exotransferase also inhibits RhoA GTPase, stable dominant-negative RhoC-expressing PC-3 (PC-3/ dnRhoC) cells were produced. Dominant-negative GTPases act by entering into a nonproductive interaction with Rho guanine exchange factors (GEFs), the proteins responsible for catalyzing the exchange of GDP for GTP on the GTPase. Given that RhoC and RhoA are 91% homologous on the protein level, we speculated that they may share a common activating GEF, and therefore expression of a dominant-negative RhoC would affect RhoA activity. No significant differences in active or total RhoA levels were detected in the PC-3/ dnRhoC cells compared with the parental PC-3 or PC-3/ pcDNA3.1 vector control cells (Figure 3b ). In contrast to the observed RhoA activity, GTP-bound RhoC is reduced by B65% in the RhoC/dnRhoC cells and B60% in C3 exotransferase-treated PC-3 cells compared with the parental and vector control and cell lines ( Figure 3a) . However, there are no significant changes in total RhoC levels. These data, taken from four separate analyses, suggest that RhoC and RhoA, although highly homologous, are activated by distinct RhoGEFs in the PC-3 cells. Therefore, expression of a dominant-negative RhoC specifically decreases activity of RhoC without affecting RhoA activation. No differences in monolayer cell growth were observed between the parental, vector and dnRhoC-expressing PC-3 cells (Figure 3c ).
To determine whether expression of dominant-negative RhoC recapitulates the effect of C3 exotransferase treatment on PC-3 cells, we performed a random motility assay as before. Parental PC-3, PC-3/ pcDNA3.1 vector control and PC-3/dnRhoC stable 
H Yao et al transfectants were plated onto blue fluorescent beads overlaid onto a collagen I-coated surface, stimulated with 5 nM IGF-I and analysed 24 h later. Similar to C3 exotransferase-treated PC-3 cells, PC-3/dnRhoC transfectants displayed increased linear motility (Figure 4a) . Quantitation of the areas of phagokinetic tracks from three separate assays demonstrates that the PC-3/ dnRhoC cells have a threefold increase in the area of their phagokinetic tracks as compared with the control PC-3 cells. The effect of dnRhoC on migration and invasion was evaluated as described previously. Migration and invasion in PC-3/dnRhoC cells are approximately 2-and 2.5-fold less, respectively, than that of the control PC-3 cells (Figure 4b ). This suggests that RhoC activation promotes PC-3 cell-directed migration and invasion, but limits linear random motility.
RhoC GTPase activity affects PC-3 cell morphology One observable consequence of inhibiting RhoC GTPase activity is a profound change in PC-3 cell morphology. Figure 5A shows phase contrast, laser confocal and scanning electron micrographs of parental PC-3 (panels a, d and g), PC-3/pcDNA3.1 (panels b, e and h) and PC-3/dnRhoC (panels c, f and i) cells. Both control cell lines are relatively flat with very broad lamellipodia nearly encompassing the circumference of the cell. In contrast, the PC-3/dnRhoC cells are elongated with smaller lamellipodia located on the leading edge of the cell.
Immunofluorescent staining for actin and the cytoskeletal protein vinculin demonstrates profound differences between PC-3 and PC-3/dnRhoC cells when grown on collagen I and stimulated with IGF-I ( Figure 5A , panels j-o). In PC-3 cells the cytoskeleton appears diffuse and appears branched leading to broad deformation of the cells' lamellipodia. Vinculin that does not appear to be associated with actin bundle ends is localized in the center of the parental PC-3 cell. In contrast, colocalized actin and vinculin in PC-3/ dnRhoC cells are isolated to the tips of the protrusions at the leading and trailing ends of the cell. Actin is highly organized along the periphery of the cells in an arrangement reminiscent of concave actin bundles and the bulk of vinculin is localized throughout the main body of PC-3/dnRhoC cells.
The change in PC-3 morphology is reminiscent of the epithelial to mesenchymal transition (EMT) described for other tumor cell types (Chang et al., 2003; Bockhorn et al., 2004) . Figure 5B shows the Western blot analysis for molecular markers associated with EMT: ZO-1, Eand N-cadherin. As typically described for other cell types undergoing EMT, a switch in expression of E-to N-cadherin and a decrease in ZO-1 are observed in the PC-3/dnRhoC cells ( Figure 5B ), suggesting that RhoC may act as a molecular switch for an EMT-like change in PC-3 cells.
RhoC GTPase activation influences expression and activation of Rac1 and Cdc42
A reciprocal relationship between RhoA and Rac1/ Cdc42 activity has been described for motile NIH3T3 cells (Sander et al., 1999; Zondag et al., 2000) . To determine whether other members of the Rho GTPase family are affected by changes in RhoC activity, we performed Western blot analysis and GTPase activity assays for Rac1 and Cdc42. Both Rac1 and Cdc42 are implicated in cellular motility, specifically through the formation of lamellipodia and filopodia, respectively, and are therefore prime candidates for mediating the observed changes in the morphologic characteristics of PC-3 cells (Ridley and Hall, 1992a, b; Ridley et al., 1992; Nobes and Hall, 1995) . The process of linear motility requires coordinated changes in Rac1 and Cdc42 activity. Therefore, we determined the expression and activation profile of these two GTPases over an extended time course using conditions similar to the random motility assay. Serum-starved PC-3 and PC-3/ dnRhoC cells were plated onto collagen I, stimulated with IGF-I and analysed 0, 5, 15, 60, 120 and 180 min after stimulation. Quantitative changes in Rac1 and Cdc42 expression and activation are observed in PC-3/ Figure 6A ). In the PC-3 cell line, a low, persistent level of Rac1 and Cdc42 activation is observed throughout the time course ( Figure 6A ). In contrast to parental cells, PC-3/dnRhoC cells display a marked increase in expression and activation of both Rac1 and Cdc42 at 60 min after IGF-I stimulation, which persists up to 180 min ( Figure 6A ). Of particular note is a striking increase in Cdc42 expression from 0 to 60 min after stimulation.
Requirement of RhoC
Interestingly, levels of phosphorylated Rac1 and Cdc42 are reduced in PC-3/dnRhoC-and C3-treated PC-3 cells grown on collagen I and stimulated with IGF-I for 60 min ( Figure 6B ). Rac1 and Cdc42 are phosphorylated on serine 71 and in vitro assays suggest that phosphorylation of Rac1 inhibits the exchange of GDP for GTP (Kwon et al., 2000) . Thus, decreased phosphorylation of Rac1 may contribute to an increase in Rac1 and Cdc42 activity.
RhoC GTPase activity modulates focal adhesion protein activation and localization The phenotypic changes observed in PC-3/dnRhoC cells are identical to those previously described for cells transfected with a paxillin deletion mutant (West et al., 2004) . Specifically, CHO.K1 fibroblasts transfected with paxillin lacking the LD4 domain, which binds paxillin kinase linker (PKL), demonstrate increased linear motility, decreased invasion and increased, persistent Rac1 activation (West et al., 2004) . With this in mind, we determined the effect of RhoC activation on focal adhesion proteins. Total and phosphorylated focal 
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H Yao et al adhesion kinase (FAK) and phosphorylated paxillin levels were decreased in the PC-3/dnRhoC cells, whereas total paxillin and PKL protein levels essentially remained unchanged ( Figure 7A ). More interestingly, immunoprecipitation experiments demonstrate that the interaction of PKL with paxillin is decreased in PC-3/ dnRhoC cells ( Figure 7B ). In contrast, FAK and PKL or FAK and paxillin coimmunopreciptated, indicating that their interaction was not altered ( Figure 7A ). Next, colocalization of paxillin with FAK (panel a), PKL with FAK (panel b) and paxillin with PKL (panel c) was determined ( Figure 7C ). All of the focal adhesion proteins colocalize within the cell, but the distribution of these proteins is altered in PC-3/dnRhoC cells compared with the parental PC-3 line ( Figure 7C ). Fluorescent localization demonstrated that FAK and PKL colocalize in both PC-3 and PC-3/dnRhoC cells. Paxillin also colocalized with both FAK and PKL in these cells. However, in the PC-3/dnRhoC cells, PKL is found independent of paxillin in the cytoplasm of the cells (white arrows; Figure 7C vi). These data suggest that the changes in cell motility, migration and invasion due to inhibition of RhoC activity may be because of alterations in the localization, activity and interaction of focal adhesion proteins. Furthermore, taken with the alterations seen in the distribution of the actin cytoskeleton, these data may indicate turnover of focal adhesions to focal complexes (Kaverina et al., 2002) .
Discussion
The ability of CaP cells to invade and metastasize, particularly to bone, has been an area of intense research. Bone contains high levels of IGF ligands, which are intimately involved in normal bone turnover and are implicated in metastasis (Chung et al., 2005) . IGF-I not only acts as a mitogenic factor for cells, but also stimulates cellular motility (reviewed in (Cooper and Pienta, 2000; van Golen, 2003) ). IGF-I potentially regulates tumor cell motility through the activity of the Rho GTPases (van Golen, 2003) . In particular, IGF-I stimulation of Rac1 in neuroblastoma cells and RhoA and RhoC in breast cancer cells is well studied (Jackson et al., 2001; Meyer et al., 2001; Tanno et al., 2001; Lopez and Hanahan, 2002) . Several laboratories, including our own in the present study, have demonstrated that IGF-I acts as a chemoattractant for CaP cells Cooper and Figure 6 Expression and activation of Rac1 and Cdc42 in PC-3 cells are increased when RhoC GTPase is not active. Panel A, to determine the duration of Rac1 and Cdc42 expression and activation, serum-starved PC-3 and PC-3/dnRhoC cells were plated on collagen I, stimulated with IGF-I and harvested at 0, 5, 15, 60, 120 and 180 min. Immunoblot analysis is shown in (a). An aliquot of 30 mg total protein was taken to determine total Rac1 or Cdc42 levels; the remainder of the protein lysates was used to determine levels of active GTPase. Densitometry was performed on each of the samples and a ratio of GTP versus total protein was determined and is shown for the duration of the time course (b). PC-3 cells (') are represented by the dashed line and the dnRhoC cells (m) by the solid line. A separate panel (c) shows the changes for Rac1 observed in the first 15 min of the experiment. The t ¼ 0 value of parental PC-3 cells was set to 1 and all other values were measured against it. The values shown are averages from at least three separate experiments. Panel B shows the immunoblot analysis for total and serine 71 phosphorylated Rac1 and Cdc42. PC-3, PC-3/pcDNA3.1 vector and PC-3 dnRhoC cells were grown on collagen I, stimulated with 5 nM IGF-I and protein harvested 60 min later. A 50 mg aliquot of each protein was analysed by immunoblotting with monoclonal antibodies specific for Rac1, Cdc42 and phospho-Rac1/Cdc42. GAPDH was included as a loading control.
Requirement of RhoC GTPase for prostate cancer invasion H Yao et al Pienta (2000) . Furthermore, collagen I, an integral component of mineralized bone matrix, affects CaP cell migration and invasion through integrin activation (Keely et al., 1998; Jaffe and Hall, 2002) . Through interplay of growth factor and integrin signaling, Rho
GTPases are temporally and spatially activated, allowing tumor cells to successfully invade, survive and grow at distant sites (Keely et al., 1998; Jaffe and Hall, 2002) . Thus, growth factor and integrin signaling provide two potential stimuli for Rho activation (Cooper and Pienta, Figure 7 Inhibition of RhoC leads to changes in expression and distribution of focal adhesion proteins. Panel A shows the Western blot analysis for phosphorylated and total focal adhesion kinase (FAK), paxillin and paxillin kinase linker (PKL). Aliquots of 50 mg total protein were analysed for phosphorylated and total protein levels. Relative ratios of phosphorylated to total protein levels are shown for FAK and paxillin. Relative levels of total PKL are also shown. Densitometry measurements are the averages of three independent experiments. The value for the PC-3 parental cells was set at 1 and all other values were measured against it. Panel B interaction of focal adhesion proteins was determined by immunoprecipitation of 500 mg total protein that was pre-cleared with normal IgG followed by immunoblotting. Normal IgG negative controls did not produce bands when immunoblotted with antibodies specific for FAK, paxillin or PKL. Measurement of the relative levels of PKL detected in the paxillin immunopreciptiations is shown. The value for the parental PC-3 cells was set at 1 and all other values were measured against it. Measurements are the average of three independent experiments. Panel C shows the immunfluoresence for (a) paxillin (i and iv) and FAK (ii and v) with merge (iii and vi), (b) PKL (i and iv) and FAK (ii and v) with merge (iii and vi), (c) paxillin (i and iv) and PKL (ii and v) with merge (iii and vi). The arrows indicate that PKL is not associated with paxillin.
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. Therefore, we chose to investigate the role of RhoC GTPase in IGF-I and/or collagen I-stimulated motility, migration, invasion and morphological alterations in PC-3 cells. Clearly, the Rho GTPases play a central role in tumor cell invasion and metastasis (Sahai and Marshall 2002) . To date, few studies have attempted to define the Rho GTPase profile of metastatic CaP cells. A recent study by Hodge et al. (2003) suggests that increased RhoA expression and activity are responsible for NF-kBmediated PC-3 cell invasion. The invasive capabilities of highly metastatic PC-3 variants, but not of low metastatic variants, were increased by introducing a constitutively active form of RhoA into the cells (Hodge et al., 2003) . Our data suggest that RhoA is a component in the motile and invasive phenotype of PC-3 cells; however, we were unable to find a difference in RhoA expression in our PC-3/dnRhoC transfectants that could account for the in vitro differences in invasion detected, compared with parental PC-3 cells. Other groups have demonstrated that RhoA and Cdc42 activation is involved in cytoskeletal reorganization of CaP cells. Activation of the G-protein-coupled receptors called protease-activated receptors (PARs) results in activation of RhoA and other members of the Rho GTPase family (Greenberg et al., 2003) . Stimulation of LNCaP cells with PAR-activating peptides, trypsin or thrombin leads to increased stress fiber formation and filopodia formation (Greenberg et al., 2003) . Similar cytoskeletal reorganization and activation of RhoA and Cdc42 is observed when PC-3U cells (a subline of PC-3) are stimulated with transforming growth factor-b (Edlund et al., 2002) . Although these studies demonstrate a role for these GTPases in CaP cell cytoskeletal reorganization, they have not fully made the connection with motility, invasion or metastasis. Further, it is becoming increasingly evident that the vast majority of human tumors overexpress RhoA, but overexpression of RhoC is limited to particularly aggressive and metastatic forms of cancer (Moscow et al., 1994; del Peso et al., 1997; Fritz et al., 1999; Imamura et al., 1999; Clark et al., 2000; Sahai and Marshall, 2002; Carr et al., 2003; Horiuchi et al., 2003; Kamai et al., 2003; Marionnet et al., 2003; Shinto et al., 2003; Wang et al., 2003; Kondo et al., 2004) The PC-3 cells, derived from a bone metastasis, were the only CaP cell line to express active RhoC protein.
Interestingly, we demonstrate that when PC-3 cells are tested for random motility using collagen I as a substrate and IGF-I as a stimulant; the phagokinetic tracks produced suggest that the cells are anchored at one end allowing them to only move in a circular pattern. Yet, they are highly motile in directed migration, haptotaxis and invasion assays. In contrast, when RhoC is inhibited, the cells become highly randomly motile but do not invade. Changes in PC-3 cell morphology, reminiscent of EMT described for other tumor cell types, is observed when RhoC is inhibited (Chang et al., 2003; Bockhorn et al., 2004) . Accompanying the changes in morphology, we distinguish changes in protein expression of the EMT markers ZO-1, E-and N-cadherin. These data suggest that in PC-3 cells, RhoC may act as a determinant switch for EMT.
Collard's group was the first to demonstrate that RhoA GTPase and Rac1 are in a reciprocal relationship of activation during cellular motility and invasion (Sander et al., 1999; Zondag et al., 2000) . In the current study, we demonstrate that when RhoC is inhibited in PC-3 cells there is a marked upregulation of Rac1 and Cdc42 expression and activation. In addition, in PC-3/ dnRhoC cells, we observe changes in expression, activation and distribution of focal adhesion proteins. These changes likely represent a switch from focal adhesions, which are associated with stable adhesion, to focal complexes, present during active cell motility, that are typically formed through Rac1 and Cdc42 activity (Kaverina et al., 2002) . The changes in morphology, Rac1 GTPase activation, random motility and invasion are similar to those observed in paxillin deletion mutants (West et al., 2004) . Deletion of the LD4 domain of paxillin results in redistribution of PKL to the cytoplasm of CHO.K1 fibroblasts. As a result, cellular morphology changes, cellular protrusiveness increases, random motility increases and invasion decreases, suggesting an increase in focal complex formation. These cells also have increased Rac1 expression and prolonged Rac1 activity. Therefore, disrupted interaction between paxillin and PKL promotes prolonged Rac activity and extended linear motility. In our study, we observe a decreased interaction between paxillin and PKL in the PC-3/dnRhoC cells. We have measured a slight decrease in PKL expression in the PC-3/dnRhoC cells, which could account for the decreased paxillin/ PKL interaction. However, we also observed a large amount of PKL in the cytoplasm of the cells suggesting that PKL is localized away from paxillin.
Paxillin is present in both focal complexes and focal adhesions and is one of the earliest proteins recruited to these structures by either integrin engagement or growth factor stimulation (Turner, 2000; Zaidel-Bar et al., 2003) . Rac-1 promotes focal complex formation, whereas Rho kinase inhibition induces focal adhesion disassembly, also resulting in increased focal complex formation (Zaidel-Bar et al., 2003) . Our observations suggest that high levels of active RhoC in cells may induce paxillin/PKL interaction, thus reducing the prolonged Rac activation associated with focal complex formation, leading to a reduction in cellular protrusions and associated random motility. Since focal complexes are rather short-lived structures, active RhoC inhibition of focal complex formation could in turn promote more directed migration through stable focal adhesion formation and/or extended interactions with ECM.
In summary, our data suggest an inverse relationship of active RhoC with Rac1 and Cdc42 in PC-3 cells. RhoC activity promotes IGF-I-stimulated migration and invasion while limiting linear motility. In contrast, when RhoC activation is inhibited, Rac1 and Cdc42 activity increase, promoting linear motility. Concurrently, there is a switch reminiscent of an epithelial to mesenchymal morphology. Expression, activation and localization of focal adhesion proteins are also affected.
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Thus, RhoC appears to act as a critical and dynamic switch controlling PC-3 cell linear and directed movement. Our laboratory is currently exploring the convergence of growth factor and integrin downstream signaling and its effect on Rho GTPase activation.
Materials and methods
Cell culture
All CaP cell lines were obtained from American Type Culture Collection (Manassas, VA, USA). The LNCaP cells were each maintained in 90% RPMI-1640 with 2 mM L-glutamine, 1.5 g/l sodium bicarbonate, 4.5 g/l glucose, 10 mM HEPES, 1 mM sodium pyruvate and 10% fetal bovine serum (FBS, Gibco, Carlsbad, CA, USA). The DU145 cells were propagated in Eagles minimal essential medium with Earles BSS, 2 mM Lglutamine, 1.5 g/l sodium bicarbonate, 0.1 mM nonessential amino acids, 1.0 mM sodium pyruvate and 10% FBS (Gibco). The PC-3 cells were maintained in Ham's F-12 medium with 1.5 g/l sodium pyruvate, 2 mM L-glutamine and 10% FBS (Gibco). PC-3 transfectants were maintained in the same medium as the parental PC-3 cells with the addition of 250 mg/ ml Neomycin (Gibco). All cell lines were maintained at 371C in a 10% CO 2 incubator. C3 exotransferase was introduced into cells as previously described using a lipid transfer-mediated method and treated for 16 h before analysis (van Golen et al., 2000) .
Plasmids and transfections Dominant-negative RhoC (dnRhoC) in pcDNA3.1 was obtained from Gutherie cDNA Resource center (Sayre, PA, USA). Empty pcDNA3.1 was used as a vector control transfectant (Invitrogen, Carlsbad, CA, USA). The dnRhoC or empty vector was introduced into PC-3 cells using FuGene6 transfection reagent (Roche, Indianapolis, IN, USA) and selecting cells in 250 mg/ml Neomycin. Expression of the transgene was confirmed by RT-PCR.
Anchorage-independent growth assays For anchorage-independent growth assays, a 2% stock of sterile, low-melt agarose was diluted 1:1 with 2 Â MEM. Further dilution to 0.6% agarose was made using 10% FBScontaining growth medium and 1 ml added to each well of a six-well plate as a base layer. The cell layer was prepared by diluting agarose to 0.3, 0.6 or 0.9% with 10 3 cells in 2.5% FBScontaining growth medium/1.5 ml/well. A 1 ml layer of medium was maintained on top of the agar to provide nutrients. Colonies X100 mm in diameter were counted after 2-week incubation at 371C in a 10% CO 2 incubator.
RT-PCR
Semi-quantitative RT-PCR for RhoC and RhoA expression was performed as previously described using primers specific for RhoC, RhoA or as a control, GAPDH (van Golen et al., 2000a, b) . Briefly, total RNA was harvested from cells using Trizol reagent (Life Technologies, Gaithersburg, MD, USA) and cDNA was made using the AMV-reverse transcriptase kit (Promega, Madison, WI, USA). RhoC and RhoA transcripts were PCR amplified from cDNA aliquots using a 1:1000 dilution of Rho-specific primers mixed with GAPDH primers. PCR products were separated on a 1.2% TAE agarose gel and visualized with ethidium bromide. The relative intensities of the Rho and GAPDH bands were measured using an Alpha Imager 2200 (Alpha Innotech, Co., San Leandro, CA, USA).
MTT assay
Monolayer growth was measured using MTT (Sigma Chemical Co.) as previously described (van Golen et al., 2000) . Briefly, cells were plated at densities ranging from 100 to 10 000 cells in 200 ml growth medium in six replicate wells of a 96-well plate and incubated in a 371C incubator under 10% CO 2 . Cell growth was measured at 0, 1, 2, 3 and 5 days after plating. For the 0 daytime point plates were centrifuged at 1000 r.p.m. in Sorvall refrigerated tissue culture centrifuge. A 40 ml aliquot of 5 mg/ml MTT was added to the cultures for 1 h at 371C. The medium was aspirated and 100 ml DMSO (Sigma Chemical Co.) was added to each well to solubilize the formazon dye. Absorbance was read on a Dynatech microplate reader at 590 nm.
Western blot analysis
Protein was harvested from cells using RIPA buffer as previously described (van Golen et al., 2000a, b) . Lysates were separated by SDS-PAGE on a 12% gel, transferred to nitrocellulose, blocked and probed with a polyclonal antibody for RhoC (Kleer et al., 2002) or monoclonal antibodies for RhoA (Cytoskeleton, Denver, CO, USA), Rac1, Cdc42 and phospho-Rac1/Cdc42 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), E-cadherin (a gift from Dr Peggy Wheelock), Ncadherin, PKL (BD Transduction Laboratories, San Diego, CA, USA), FAK (Santa Cruz and Biolegend, San Diego, CA, USA), phospho-FAK, paxillin and phospho-paxillin (Biolegend). After incubation with a goat anti-rabbit-HRP or goat anti-mouse-HRP antibody (Santa Cruz), immunoblots were developed with ECL, exposed to Hyperfilm (Amersham, Piscataway, NJ, USA) and images recorded on an Alpha Image 90 documentation system (Alpha Innotech, San Leandro, CA, USA). Actin or GAPDH were used as loading controls (Sigma, St Louis, MO, USA). Whenever possible blots were first probed with the phospho-specific antibody, stripped and reprobed with an antibody to total protein. Densitometry was performed using Scion Image version 1.62. Values for the PC-3 parental line were set at 1 and all other values were measured against it.
GTPase activation assays Rho activation assay reagents were supplied to us by John Collard, PhD, at The Netherlands Cancer Institute Diekmann and Hall, 1995) and used to determine activation of RhoC in PC cells. Cells, 5-10 Â 10 6 cells/assay, were grown in fresh serum-containing medium for 16 h and lysed with ice-cold GST-FISH buffer (10% Glycerol, 50 mM Tris pH 7.4, 100 mM NaCl, 1% NP-40 and 2 mM MgCl 2 ). Protein lysates, 900 ml of 1mg/ml, were precleared with glutathione sepharose for 1 h at room temperature. The cleared lysates were incubated with GST-rhotekin-sepharose conjugate at 41C for 30 min. The agarose conjugate was collected by centrifugation, resuspended in Laemelli buffer, separated by SDS-PAGE, transferred to nitrocellulose and probed with a RhoC antibody developed by our laboratory (Kleer et al., 2002) . Densitometry was performed using an Alpha Image 950 imaging system. Motility, migration, haptotaxis and invasion assays Random motility assays were also performed using blue fluorescent bead motility HitKit (Cellomics, Pittsburg, PA, USA), which is based on the colloidal gold random motility assay (Albrecht-Buehler, 1977; van Golen et al., 2000a, b) . Cells, 200/well in SFM, were seeded onto a lawn of blue fluorescent beads in a BSA-coated 96-well plate (BD Biosciences). Cells were stimulated 1 h later with 10% FBS, incubated 6 h at 371C and fixed. Cells were visualized by fluorescent microscopy, digitally recorded and the areas of phagokenetic tracks measured using Scion Image.
The directed migration assay was performed using an uncoated Transwell filter with 8 mm pores (Costar, Corning, NY, USA). The lower chamber of the filter was filled with either serum-free medium or serum-free medium containing 5 nm IGF-I. The Matrigel and collagen I invasion assays were performed as previously described using precoated Transwell filters with 8 mm pores (Hendrix et al., 1987; van Golen et al., 2000a, b) . Cells were harvested and resuspended in serum-free medium containing 0.1% BSA at a concentration of 3.75 Â 10 5 cells/ml, and 0.5 ml was added to the top chambers. The haptotaxis assay was performed similar to the migration assay, except that 1 nM IGF-I was added to the top chamber with the cells. The chambers were incubated for 24 h at 371C in a 10% CO 2 incubator. The cell suspension was aspirated from the top chamber of all three assays. Excess Matrigel or collagen was removed from the invasion assay filter using a cotton swab. The filters were then cut away from the Transwell assembly, fixed top side down with methanol to a glass microscope slide, stained with H&E and the entire surface of the filters counted. In the directed migration, haptotaxis and invasion assays, the number of cells that moved in the serumfree controls was considered as background and was subtracted from the number of cells counted in the samples containing chemoattractant.
Scanning electron microscopy
Scanning electron microscopy (SEM) was performed as previously described . Briefly, cells (12 000) grown on collagen I were fixed with buffered 2.5% glutaraldehyde for 1 h, rinsed with phosphate-buffered saline (PBS) and postfixed for an additional hour with buffered osmium tetroxide. After dehydration in ascending strengths of ethanol, the cells were critical-point dried, mounted onto standard SEM stubs and gold-sputter coated. They were viewed using an AMRAY 1000-B scanning electron microscope housed at the University of Michigan Microscopy and Imaging Laboratories (MIL).
Immunofluorescence PC-3 and PC-3/dnRhoC cells were grown on collagen I-coated coverslips (BD Biosciences, San Diego, CA, USA) until 70% confluence, serum-starved for 16 h, stimulated with 5 nM IGF-I for 60 min, rinsed three times with 1 Â PBS pH 7.4 and fixed with 4% paraformaldehyde in PBS for 20 min at room temperature. After fixation, cells were rinsed three times with 1 Â PBS and blocked with 5% normal goat serum (NGS, Jackson ImmunoResearch Labs, West Grove, PA, USA) in 1 Â PBS pH 7.4 with 0.3% Triton X-100 for 1 h at room temperature. Immunfluorescence was performed using antibodies specific for vinculin (monoclonal: Calbiochem, San Diego, CA, USA), FAK (monoclonal: Biolegend), paxillin (monoclonal and polyclonal: Biolegend), PKL (monoclonal: BD Transduction Laboratories) and rhodamine-phallodin (Invitrogen Molecular Probes). Double staining of cells was performed using antibodies from different hosts. Primary antibodies were diluted in 2%NGS in 1 Â PBS pH 7.4 with 0.3% Triton X-100 for 3 h at room temperature in a humidified chamber. After rinsing with PBS, cells were incubated with a species-specific secondary antibody conjugated to a fluorescent tag for 1.5 h at room temperature. Excess antibody was rinsed with PBS, and cells were treated with anti-Fade (Invitrogen Molecular Probes, Eugene, OR, USA), mounted onto SuperPlus slides (Corning, NY, USA) with Gel Mount (Biomedia, Foster City, CA, USA) and sealed with clear nail polish. Immunfluorescence was performed on a Zeiss Scanning Laser Confocal Microscopy housed in the University of Michigan MIL.
Statistical analysis
All experiments were performed a minimum of three separate times and statistical analysis of the combined experiments was performed by the University of Michigan Biostatistics Core.
Abbreviations
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